Home » Archives for Harald » Page 57

Author Archives: Harald

CRE Surveillance Data from France

Posted on by — No Comments ↓

Despite all the concern about the emergence of CRE pathogens worldwide, it is quite difficult to obtain hard quantitative, prospectively collected incidence figures. A recent article by Robert [1] and colleagues provides useful data from France.  Using a practical definition of carbapenem-non-susceptibility (ertapenem > 0.5, imipenem, meropenem > 2, doripenem > 1), Continue reading CRE Surveillance Data from France→

QIDP Drugs: Here They Are, All of Them

Posted on by — No Comments ↓

For the latest QIDP listing, please click HERE As of Oct. 9, 2014, there were by my accounting 30 compounds with QIDP designation. Here is the break-down:   31 compounds with QIDP designation 29 antibacterials, 2  antifungals 22 systemically active, 9 for topical administration 13 in Phase 3, 9 in Phase Continue reading QIDP Drugs: Here They Are, All of Them→

What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?

Posted on by — No Comments ↓

Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name.  ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Pharmaceuticals a few years ago.  This is the ‘Carbavance’ which Continue reading What’s in a Name?  Would ‘Carbavance’ Still Smell as Sweet?→